JEREMY KELLEY: Open Payments
NPI 1952557498 · DEMOPOLIS, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,288 in 112 payments from 17 companies in 2025. Trend: 2023 $3,044 · 2024 $2,644 · 2025 $2,288
Long term medical supply or device loan: $1,200Food & beverage: $1,088
| Company | Payments | Amount |
|---|---|---|
| AngioDynamics, Inc. | 1 | $1,200 |
| Novartis Pharmaceuticals Corporation | 63 | $224 |
| United Therapeutics Corporation | 6 | $160 |
| PFIZER INC. | 9 | $155 |
| Actelion Pharmaceuticals US, Inc. | 6 | $114 |
| Novo Nordisk Inc | 5 | $82 |
| Amgen Inc. | 5 | $81 |
| Merck Sharp & Dohme LLC | 5 | $78 |
| E.R. Squibb & Sons, L.L.C. | 3 | $49 |
| Alnylam Pharmaceuticals Inc. | 2 | $36 |
Products named: VenaCure 1470 Pro, LEQVIO, VYNDAQEL, Tyvaso, UPTRAVI, Wegovy, REPATHA, VERQUVO.
Industry payments across AL — which companies pay providers there.
